Premium
Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease
Author(s) -
STERN G.M.,
LEES A.J.,
HARDIE R.J.,
SANDLER M.
Publication year - 1983
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1983.tb01524.x
Subject(s) - selegiline , parkinson's disease , medicine , disease , amphetamine , pharmacology , dopamine
— The clinical pharmacology concerned in the evolution of deprenyl as an adjuvant in the treatment of Parkinson's disease is briefly reviewed, with an assessment of its therapeutic potential. Experiments to clarify its mode of action are described, indicating that its clinical effects do not depend upon its amphetamine metabolites.